GeoVax Completes Key Milestones, Eyes Phase 3 Trial for Mpox Vaccine
GOVX sits 18% above its 52-week low of $0.639.
Summary
GeoVax has completed manufacturing, regulatory, and preclinical milestones for its GEO-MVA mpox/smallpox vaccine, clearing the path for a pivotal Phase 3 immune-bridging study. The company has GMP clinical product ready, aligned with EMA on an expedited pathway, and generated positive preclinical immunogenicity data versus the licensed MVA-BN vaccine. A 500-participant trial is set to start in Q4 2026 with results expected mid-2027. This follows a period of severe cash constraints—the last 10-Q showed only $3.1M in cash, funding operations only into September 2026—making the program's advancement a critical value driver. The news de-risks the asset and positions GeoVax for potential government procurement contracts, though financing risk remains acute.
At the time of this announcement, GOVX was trading at $0.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5M. The 52-week trading range was $0.64 to $20.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: EQS.